Tocilizumab vs bevacizumab in critically ill COVID-19 patients: Registry-based prospective study
{{output}}
Objectives: Tocilizumab, an interleukin-6 (IL-6) inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, have been used in critically ill COVID-19 patients for cytokine storm. We performed a registry-ba... ...
